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Abstract
Background: We have previously investigated the microlocalisation of M1 and M2 macrophages in NSCLC. This study
investigated the non-macrophage (NM) expression of proteins associated with M1 and M2 macrophages in NSCLC.
Methods: Using immunohistochemistry, CD68
+ macrophages and proteins associated with either a cytotoxic M1 phenotype
(HLA-DR, iNOS, and MRP 8/14), or a non-cytotoxic M2 phenotype (CD163 and VEGF) were identified. NM expression of the
markers was analysed in the islets and stroma of surgically resected tumours from 20 patients with extended survival (ES)
(median 92.7 months) and 20 patients with poor survival (PS) (median 7.7 months).
Results: The NM expression of NM-HLA-DR (p,0.001), NM-iNOS (p=0.02) and NM-MRP 8/14 (p=0.02) was increased in ES
compared to PS patients in the tumour islets. The tumour islet expression of NM-VEGF, was decreased in ES compared to PS
patients (p,0.001). There was more NM-CD163 expression (p=0.04) but less NM-iNOS (p=0.002) and MRP 8/14 (p=0.01)
expression in the stroma of ES patients compared with PS patients. The 5-year survival for patients with above and below
median NM expression of the markers in the islets was 74.9% versus 4.7% (NM-HLA-DR p,0.001), 65.0% versus 14.6% (NM-
iNOS p=0.003), and 54.3% versus 22.2% (NM-MRP 8/14 p=0.04), as opposed to 34.1% versus 44.4% (NM-CD163 p=0.41)
and 19.4% versus 59.0% (NM-VEGF p=0.001).
Conclusions: Cell proteins associated with M1 and M2 macrophages are also expressed by other cell types in the tumour
islets and stroma of patients with NSCLC. Their tissue and cellular microlocalisation is associated with important differences
in clinical outcome.
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Introduction
Lung cancer is responsible for more deaths worldwide than any
other cancer [1] and non-small cell lung cancer (NSCLC) accounts
for the majority of these cases. Even with optimal presentation
characterised by good performance status and early tumour stage,
the 5 year survival is only 67% [2]. Virchow was the first to note the
presence of leucocytes in neoplastic tissues in 1863 and suggested a
connection between inflammation and cancer [3]. It is now accepted
that both innate and adaptive immunity play a major role in cancer
development and modulation [4–6], and that most tumours arise
within an immune-permissive environment [6]. However, the
immune mechanisms regulating tumour development and progres-
sion are poorly understood at both the cell and molecular levels.
Understanding and then manipulating these immunological path-
ways may offer novel approaches to cancer therapy [7].
One recurring weakness in many studies which have investigated
the immune response within tumour tissues in the lung and
elsewhere has been the tendency to analyse the tumour stroma
and epithelial cell clusters (or islets) as a whole. However, the tissue
microenvironment plays a major role in determining the phenotype
and function of numerous structural and inflammatory cells. Thus
the role of cells within the stroma is likely to be quite different to
those in the tumour islets. In support of this statement, we have
demonstrated previously that the microlocalisation of immune cells
in tumour sub-compartments (islets or stroma) in NSCLC has a
profound influence on survival [8]. Specifically, we noted a marked
survival advantage for patients with increased numbers of macro-
phages in their tumour islets irrespective of tumour stage [8], a
finding which has been confirmed by others in an independent
cohort [9]. It is also well recognised that there are two major
macrophage phenotypes [10–13], M1 (classically activated) and M2
(alternatively activated). We have shown previously in NSCLC that
HLA-DR, inducible nitric oxide synthase (iNOS), myeloid related
protein 8/14 (MRP 8/14) and tumour necrosis factor-alpha (TNFa)
are markers of M1 (cytotoxic) macrophages and that CD163 and
vascular endothelial growth factor (VEGF) are markers of M2 (non-
cytotoxic) macrophages [14]. Of significance, we demonstrated that
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cytotoxic M1 phenotype and are associated with extended survival
supporting the view that the survival advantage conferred bytumour
islet macrophage infiltration is related to their cytotoxic potential.
HLA-DR [15], iNOS [16], MRP 8/14 [17] and TNFb [18]
have been associated with improved survival in NSCLC in
previous studies. It was suggested that TNFa expression is not
associated with survival [18], but we have shown recently that its
expression within the tumour islets correlates with improved
survival, while its expression in the tumour stroma predicts poor
survival [19]. Because expression of these cell proteins by
macrophages is linked strongly to NSCLC survival, we have
now determined whether this applies to these markers expressed
by other cell types.
Methods
Study Population
The study was approved by the Leicestershire Research Ethics
Committee (approval reference number 6529). All patients gave
their written consent at time of surgery for donation of tissue but
informed consent was not obtained for each patient for this study as
they had died at the time of analysis. The Leicestershire Research
Ethics Committee approved the consent procedure for those who
died. The tissue specimens evaluated were from 40 patients with
NSCLC who had undergone resection with curative intent at the
University Hospitals of Leicester National Health Service Trust
(Leicester, United Kingdom). These patients had resections during
two periods – one dating from 1991 to 1994 and the second from
January to December 1999. This cohort of patients has been
described previously [8] and these 40 patient samples examined
before [14]. Patients were selected for the study based on their
survival, without knowledge of their previous tumour cell counts. 20
patients had extended survival (ES) (mean 92.7 months, S.E.M.7.2),
and 20 patients had poor survival (PS) (mean 7.7 months, S.E.M.
0.7). This method of patient selection has been used previously
[14,19,20,21,22]. Patient characteristics are shown in Table 1.
Immunohistology
The specimens studied were formalin fixed and paraffin
embedded. Only blocks containing the advancing edge of the
tumour were evaluated. Tissue sections of 4 mm thickness were cut
onto glass slides and then de-waxed in xylene and rehydrated
through graded alcohols. Antigen retrieval was carried out using
Trilogy Antigen Retrieval solution (Cell Marque, Hot Springs,
United States of America) in a pressure cooker (heated to 117.5uC
for 1 min and then cooled to 100uC for 30 seconds). Mouse
antihuman macrophage CD68 mAb (clone PGM1; Dakocytoma-
tion, Ely, Cambridgeshire, United Kingdom) was used as a specific
marker for macrophages. Antibodies for phenotype were all mouse
antihuman as follows: i) CD163 mAb (clone 10D6, Novocastra,
United Kingdom), ii) HLA-DR mAb (clone TAL.1B5; Hycult
biotechnology, the Netherlands), iii) iNOS mAb (clone 2D2-B2;
R&D systems, Abingdon, United Kingdom), iv) MRP 8/14 mAb
(clone 27E10; Bachem Distribution Services, Germany), and vi)
VEGF mAb (clone 14–124; Abcam, Cambridge, United King-
dom). IgG1 mAb (clone DAK-GO1; Dakocytomation) was used as
an isotype control. Immunostaining for CD68 and each individual
phenotype marker was performed using the Envision double-stain
kit (Dakocytomation) according to the manufacturer’s instructions
and as described previously(8). Thus, six slides were prepared for
each patient – CD68 versus CD163, CD68 versus HLA-DR,
CD68 versus iNOS, CD68 versus MRP 8/14, and CD68 versus
VEGF. CD68 was developed with peroxidase and 3,39-diamino-
benzidine tetrahydrochloride (brown reaction product), and each
phenotype marker with alkaline phosphatase and fast red (red
reaction product). Sections were then counterstained with
haematoxylin and mounted in an aqueous mounting medium
(BDH Chemicals Ltd, Poole, United Kingdom). Appropriate
isotype controls were performed where the primary antibodies
were replaced by irrelevant mouse mAb of the same isotype and at
the same concentration as the specific primary mAb.
Analysis and Validation of Immunostaining
Analysis was performed blind with respect to the clinical
outcome. The ten most representative high-power fields (6400)
per slide were manually selected using an Olympus BX50
microscope (Olympus, Southall, United Kingdom). The respective
areas of stroma and of tumour-cell islets were then measured at
6400 magnification using Scion image analysis software (Based on
National Institutes of Health Image for Macintosh, modified for
Windows [Scion Corp, Frederick, MD]). The number of nucleated
macrophages and cells with positive staining for the phenotype
marker in each area were then counted manually and expressed as
Table 1. Patient characteristics.
Characteristic Extended Survival Poor Survival
No. of patients 20 20
Age – years 69.161.8 69.661.6
Male sex – no. (%) 16 (80) 11 (55)
Year of surgery – no. (%)
1991 0 (0) 1 (5)
1992 3 (15) 1 (5)
1993 2 (10) 1 (5)
1994 1 (5) 1 (5)
1999 14 (70) 16 (80)
Tumour stage – no. (%)
1 13 (65) 13 (65)
2 5 (25) 3 (15)
3a 2 (10) 3 (15)
3b and 4 0 (0) 1 (5)
Histology – no. (%)
Squamous 14 (70) 10 (50)
Adenocarcinoma 4 (20) 5 (25)
Large cell 0 (0) 3 (15)
Other 2 (10) 2 (10)
Tumour Grade – no. (%)
Well 2 (10) 0 (0)
Moderate 8 (40) 1 (5)
Poor 11 (55) 18 (90)
Not recorded 1 (5) 1 (5)
Adjuvant Chemotherapy (%) 0 (0) 0 (0)
Radiotherapy (%) 3 (15) 1 (5)
Palliative Radiotherapy (%) 2 (10) 1 (5)
Survival – months 92.767.2 7.760.7
Complete resection* 16 14
Plus-minus values are means 6 SEM.
*information on resection margins available from 18 Extended Survival patients
and 17 Poor Survival patients.
doi:10.1371/journal.pone.0021874.t001
CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 in NSCLC
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2 of stroma or tumour islets. Analysis was validated
previously [8,14,19,20].
Statistical Analysis
Statistical analyses were carried out using the GraphPad Prism
software package (v. 4.02; GraphPad Prism Software Inc, San
Diego, CA). For categoric analysis, the median value was used as a
cut point to dichotomise the series. The x
2 test was used to test for
relationships between categoric variables, and the Mann-Whitney
nonparametric test was used to compare categoric with continuous
variables. The Kruskal-Wallis one-way analysis of variance test
was used to compare multiple groups. Kaplan-Meier survival
curves were used to look for correlations with survival and were
compared with the use of the log-rank statistic. For the above
comparisons, p,0.05 was considered statistically significant.
Results
Patient Characteristics
These are shown in table 1. Of note, none of the patients
received adjuvant chemotherapy as this was the approach at time
of surgical resections in this study.
Validation of Analysis
Clear and distinguishable staining was evident for both CD68
and each phenotype marker. In addition to the double-stained
macrophages described previously [14], numerous single-stained
cells which were not macrophages were readily identifiable
(Fig. 1A–E). Appropriate isotype controls were negative. Cell
counts were repeated and an intraclass correlation coefficient was
calculated as 0.998 (p,0.001). This method of analysis has also
been validated by our group previously [8].
Cellular Distribution in Tumour Islets and Stroma
Non-macrophage (NM) expression of CD163 (NM-CD163) in
the tumour islets was similar when compared between ES and PS
patients (median 3.9 versus 5.2 cells/mm
2 respectively, p=0.39),
but expression of NM-VEGF was significantly reduced in the ES
compared to PS patients (2.1 versus 11.4 cells/mm
2 respectively,
p,0.001). In contrast, when comparing the islets of ES versus PS
patients, expression of NM-HLA-DR (111.7 versus 15.9 cells/
mm
2 respectively, p,0.001), NM-iNOS (19.7 versus 9.6 cells/
mm
2 respectively, p=0.02), and NM-MRP 8/14 (6.3 versus 2.2
cells/mm
2 respectively, p=0.02) was significantly elevated in the
ES islets. There was significantly less expression of NM-CD163 in
the islets of ES patients compared with expression of NM-HLA-
DR and NM-iNOS (p,0.001, and p,0.001respectively) (Fig. 2A).
There was also significantly less expression of NM-VEGF in the
islets of ES patients compared to NM-HLA-DR, NM-iNOS,
and NM-MRP 8/14 (p,0.001, p,0.001, and p=0.04 and,
respectively).
With respect to the tumour stroma, there was higher expression
in the stroma of ES patients compared with PS patients for NM-
CD163 (45.9 versus 22.2 cells/mm
2) (p=0.04) and lower
expression in the stroma of ES compared to PS patients for
NM-iNOS (6.4 versus 17.7 cells/mm
2, p=0.002) and NM-MRP
8/14 (3.9 versus 9.8 cells/mm
2, p=0.01) (Figs. 3A and B). There
was significantly higher expression of NM-CD163 in the stroma of
ES patients compared with expression of NM-iNOS and NM-
MRP 8/14 (p,0.001) (Fig. 3A). There was also significantly
higher expression of NM-VEGF in the stroma of ES patients
compared to NM-iNOS and NM-MRP 8/(p=0.003 and
p,0.001, respectively).
In the ES group there was higher expression of NM-CD163 and
NM-VEGF (p,0.001) in the stroma compared to the islets and
Figure 1. Immunohistology in NSCLC. In (A)–(E), CD68
+ cells are stained brown and (A) CD163 (red), (B) VEGF (red), (C) HLA-DR (red), (D) iNOS
(red) and (E) MRP 8/14 (red). Singlestain CD68 brown (white arrowhead), Singlestain non-macrophage phenotypic marker red (small arrowhead),
Double-stain cells contain both brown and red (large arrowhead).
doi:10.1371/journal.pone.0021874.g001
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compared to the stroma (p=0.002 and p,0.001) (Figs. 2A and
3A). The results are summarised in Table 2.
Kaplan-Meier Survival Analysis
For further analysis, the data were divided into two groups
above and below the median cell-count values and Kaplan-Meier
survival curves were plotted. Looking at NM staining for each
protein, there was an inverse relationship between tumour islet
density and survival for NM-VEGF (p,0.001), and significant
positive associations for NM-HLA-DR (p,0.001), NM-iNOS
(p=0.003) and NM-MRP 8/14 (p=0.04) (Fig. 4). There was also
an association between survival and tumour stroma NM-CD163
density (p=0.005), but an inverse relationship for MRP 8/14
(p=0.02) (Fig. 5).
Discussion
Macrophage infiltration of tumour islets in surgically resected
NSCLC confers a marked survival advantage independently of
tumour stage, while increasing numbers of macrophages in the
tumour stroma are associated with a worse prognosis [8]. We have
also shown previously that there are two distinct macrophage
phenotypes in NSCLC tissue: M1 macrophages that express HLA-
DR, iNOS, MRP 8/14 and TNFa, and M2 macrophages that
express CD163 and VEGF [14]. We also noted that macrophages
within NSCLC tumour islets are predominantly of the cytotoxic
M1 phenotype and are associated with extended survival. The
protein markers for macrophages are also known to be expressed
by other cell types, and the biological activity of these proteins may
therefore extend beyond their role in macrophage biology. We
have therefore examined the non-macrophage (NM) expression of
markers associated with M1 and M2 macrophages in surgically
resected NSCLC specimens. Our patients were divided into two
groups according to survival. The clinical characteristics of the
patients in both groups were well balanced with the exception of
tumour grade which was slightly worse in the poor survival group.
It was clear that cells other than macrophages expressed
CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 in both the
NSCLC tumour islets and stroma. The results were very
interesting in that the expression of NM-VEGF was lower in the
tumour islets of the ES compared to PS patients, but expression of
NM-HLA-DR, NM-iNOS and NM-MRP 8/14 was increased in
the tumour islets of ES versus PS patients. This suggests that these
proteins play an important role in tumour immunology and
disease progression.
The increased expression in the tumour islets of NM-HLA-DR,
NM-iNOS and NM-MRP 8/14 in patients with ES compared to
PS, mirrors the findings with the macrophage expression of these
markers [14]. These proteins were also relatively increased in the
ES islets compared to ES stroma, a feature reversed in the PS
patients. This suggests that NM-HLA-DR, NM-iNOS and NM-
MRP 8/14 must be expressed in the islets to fulfil their anti-
tumourigenic potential.
In contrast, macrophages expressing VEGF are increased in the
islets of ES patients, but NM-VEGF is significantly increased in
the islets of PS patients. Thus the biological outcome with respect
to VEGF expression is critically related to the cells expressing it
and their location within the tumour. We have observed similar
findings with respect to TNFa expression [19]. The important
clinical message from these observations is that if VEGF for
example is to be neutralised with novel biological therapies, it
Figure 2. Non-macrophage double-stain densities in the islets in (A) extended survival (ES) and (B) poor survival (PS). * represents a
significant difference (p,0.05) in expression compared with CD163. = represents a significant difference (p,0.05) in expression compared with VEGF.
{ represents a significant difference (p,0.05) between the corresponding marker in the ES group.
doi:10.1371/journal.pone.0021874.g002
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The major limitation of this study that will need addressing in
future work is that we have not identified the cells expressing
CD163, VEGF, HLA-DR, iNOS and MRP 8/14 as there are
numerous permutations. In addition the biological role of many of
these proteins are poorly understood, and it is uncertain whether
their association with survival is due their own function, or
whether they are markers of other pro/anti-tumourigenic activities
performed by the cells expressing them. CD163 is expressed by
differing organ-specific macrophages, including alveolar and
interstitial macrophages in the lung [23], and dendritic cells
[24], and is a member of the scavenger receptor family which
removes haemoglobin complexes from the tissue microenviron-
ment [25]. It may play a role in chronic inflammation [26] but its
role in cancer remains unclear. Nevertheless, its expression by
macrophages in the NSCLC tumour islets is associated with
improved outcome following surgery, and as shown here, its NM-
expression in the stroma also associates with ES.
VEGF is a pro-angiogenic molecule secreted in various isoforms
which acts by binding to tyrosine kinase receptors. VEGF has been
implicated in the process of tumour angiogenesis leading to
tumour proliferation [27,28], but also exerts important effects on
cellular function such as proliferation and migration [27] and so it
is easy to envisage why increased NM-VEGF in the tumour islets
would be associated with poor survival.
HLA-DR is expressed by diverse cells including mast cells [29],
natural killer cells [30] and epithelial cells. Its main function is in
antigen presentation to elicit an immune response. Monocytes
activated by tumour-derived microvesicles from pancreatic, colon
and lung cancer cell lines have been found to show increased
expression of HLA-DR and a resulting increase in production of
reactive oxygen intermediates and TNFa [31]. It is known that
HLA-DR is expressed by natural killer cells and it is therefore
possible that the survival advantage conferred by high non-
macrophage expression of HLA-DR relates to the presence of
natural killer cells in the tumour islets. Again this is compatible
with our previous findings suggesting that when cytotoxic cells, for
example macrophages [14], are present in the tumour islets,
patients have improved survival.
Figure 3. Non-macrophage double-stain densities in the stroma in (A) extended survival (ES), and (B) poor survival (PS). * represents
a significant difference (p,0.05) in expression compared with CD163. = represents a significant difference (p,0.05) in expression compared with
VEGF. { represents a significant difference (p,0.05) between the corresponding marker in the ES group.
doi:10.1371/journal.pone.0021874.g003
Table 2. Summary of the cellular distribution results in the
tumour islets and stroma indicating the median density of
cells/mm
2 in extended survival (ES) and poor survival (PS)
patients.
Islets ES Islets PS Stroma ES Stroma PS
CD163 3.9 5.2 45.9{ 22.2
VEGF 2.1* 11.4 18.6 20.1
HLA-DR 111.7* 15.9 22.6 66.6
iNOS 19.7* 9.6 6.4{ 17.7
MRP 8/14 6.3* 2.2 3.9{ 9.8
*p,0.05 compared to islets PS.
{p,0.05 compared to stroma PS.
doi:10.1371/journal.pone.0021874.t002
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HLA-DR, (D) iNOS and (E) MRP 8/14.
doi:10.1371/journal.pone.0021874.g004
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HLA-DR, (D) iNOS and (E) MRP 8/14.
doi:10.1371/journal.pone.0021874.g005
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release of TNFa [32]. MRP 8/14 is also known to be expressed by
neutrophils [33]. The antigen for MRP 8/14 has been found only
in inflammatory tissues and shown to be absent from normal
resident mononuclear phagocytes [34]. MRP 8/14 is enhanced by
IFN-c and LPS [34,35] and has bacteriostatic properties [36].
iNOS has a role in conveying protection against bacteria, viruses
and parasites as well as suppressing malignancies [37–40]. In
addition it has been proposed to have immunosuppressive effects,
including the inhibition of lymphocyte proliferation [37]. iNOS is
expressed by endothelial cells [41] as well as by arterial wall
smooth muscle cells [42]. The finding of increased NM-MRP 8/
14 and iNOS in the islets of ES patients is therefore consistent with
the previously observed anti-tumorigenic profile in the islets of
these patients. Our findings should ideally be validated in another
series.
In summary, we have shown that cells other than macrophages
express proteins associated with M1 and M2 macrophages. The
NM expression of these proteins and their relationship to clinical
outcome is again critically dependent on their microlocalisation
within the tumour. The cellular expression is also very important
as shown previously for TNF [19] and for VEGF in this study.
Thus patients who are islet macrophage-VEGF
high NM-VEGF
low
have ES, whereas those who are islet macrophage-VEGF
low, NM-
VEGF
high have PS. This has important implications for under-
standing the biology of these molecules and the delivery of novel
biological therapeutics in NSCLC.
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